FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164910651> ?p ?o ?g. }

• W2164910651 endingPage "1348" @default.
• W2164910651 startingPage "1342" @default.
• W2164910651 abstract "In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the peroxisome proliferator-activated receptor-γ (PPARγ) agonists troglitazone and ciglitazone on cyclin D1 repression. We obtain evidence that the ability of high doses of troglitazone and ciglitazone to repress cyclin D1 is independent of PPARγ activation. PPARγ-inactive troglitazone and ciglitazone analogs 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzylidene]-2,4-thiazolidinedione (Δ2-TG) and 5-[4-(1-methyl-cyclohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione are able to facilitate cyclin D1 ablation with potency similar to that of troglitazone and ciglitazone in MCF-7 cells. Reverse transcription-polymerase chain reaction shows that the mRNA level of cyclin D1 remains unaltered in drug-treated cells, indicating the repression is mediated at the post-transcriptional level. Moreover, the ablative effect of these agents is specific to cyclin D1, in that the expression levels of many other cyclins and cyclin-dependent kinases examined remain unchanged after drug treatment. Our data indicate that troglitazone- and Δ2-TG-induced cyclin D1 repression is mediated via proteasome-facilitated proteolysis because it is inhibited by different proteasome inhibitors, including <i>N</i>-carbobenzoxy-l-leucinyl-l-leucinyl-l-norleucinal (MG132), lactacystin, and epoxomicin, and is preceded by increased ubiquitination. The dissociation of these two pharmacological activities (i.e., PPARγ activation and cyclin D1 ablation) provides a molecular basis to use Δ2-TG as a scaffold to develop a novel class of cyclin D1-ablative agents. Therefore, a series of Δ2-TG derivatives have been synthesized. Among them, 5-[4-(6-allyoxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzylidene]-2,4-thiazolidinedione represents a structurally optimized agent with potency that is an order of magnitude higher than that of Δ2-TG in cyclin D1 repression and MCF-7 cell growth inhibition." @default.
• W2164910651 created "2016-06-24" @default.
• W2164910651 creator A5037474413 @default.
• W2164910651 creator A5051867478 @default.
• W2164910651 creator A5067462259 @default.
• W2164910651 creator A5071290232 @default.
• W2164910651 creator A5074982960 @default.
• W2164910651 creator A5080852182 @default.
• W2164910651 creator A5083931191 @default.
• W2164910651 creator A5085573537 @default.
• W2164910651 date "2005-01-13" @default.
• W2164910651 modified "2023-09-23" @default.
• W2164910651 title "Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells" @default.
• W2164910651 cites W1777065333 @default.
• W2164910651 cites W1976449876 @default.
• W2164910651 cites W1983416626 @default.
• W2164910651 cites W1992772703 @default.
• W2164910651 cites W2001775703 @default.
• W2164910651 cites W2002276672 @default.
• W2164910651 cites W2009012471 @default.
• W2164910651 cites W2019695814 @default.
• W2164910651 cites W2020286683 @default.
• W2164910651 cites W2025391956 @default.
• W2164910651 cites W2027304309 @default.
• W2164910651 cites W2052430038 @default.
• W2164910651 cites W2074356752 @default.
• W2164910651 cites W2085448417 @default.
• W2164910651 cites W2089687829 @default.
• W2164910651 cites W2098660054 @default.
• W2164910651 cites W2098953839 @default.
• W2164910651 cites W2108958930 @default.
• W2164910651 cites W2109069210 @default.
• W2164910651 cites W2121664015 @default.
• W2164910651 cites W2132244436 @default.
• W2164910651 cites W2138798180 @default.
• W2164910651 cites W2142095017 @default.
• W2164910651 cites W2145295538 @default.
• W2164910651 cites W2147746178 @default.
• W2164910651 cites W2152336497 @default.
• W2164910651 cites W2155984740 @default.
• W2164910651 cites W2160971992 @default.
• W2164910651 cites W2163207549 @default.
• W2164910651 cites W2170906235 @default.
• W2164910651 cites W2305277255 @default.
• W2164910651 doi "https://doi.org/10.1124/mol.104.007732" @default.
• W2164910651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15653552" @default.
• W2164910651 hasPublicationYear "2005" @default.
• W2164910651 type Work @default.
• W2164910651 sameAs 2164910651 @default.
• W2164910651 citedByCount "114" @default.
• W2164910651 countsByYear W21649106512012 @default.
• W2164910651 countsByYear W21649106512013 @default.
• W2164910651 countsByYear W21649106512014 @default.
• W2164910651 countsByYear W21649106512015 @default.
• W2164910651 countsByYear W21649106512016 @default.
• W2164910651 countsByYear W21649106512017 @default.
• W2164910651 countsByYear W21649106512018 @default.
• W2164910651 countsByYear W21649106512019 @default.
• W2164910651 countsByYear W21649106512020 @default.
• W2164910651 countsByYear W21649106512021 @default.
• W2164910651 countsByYear W21649106512023 @default.
• W2164910651 crossrefType "journal-article" @default.
• W2164910651 hasAuthorship W2164910651A5037474413 @default.
• W2164910651 hasAuthorship W2164910651A5051867478 @default.
• W2164910651 hasAuthorship W2164910651A5067462259 @default.
• W2164910651 hasAuthorship W2164910651A5071290232 @default.
• W2164910651 hasAuthorship W2164910651A5074982960 @default.
• W2164910651 hasAuthorship W2164910651A5080852182 @default.
• W2164910651 hasAuthorship W2164910651A5083931191 @default.
• W2164910651 hasAuthorship W2164910651A5085573537 @default.
• W2164910651 hasConcept C104317684 @default.
• W2164910651 hasConcept C120089663 @default.
• W2164910651 hasConcept C1292079 @default.
• W2164910651 hasConcept C153911025 @default.
• W2164910651 hasConcept C170493617 @default.
• W2164910651 hasConcept C185592680 @default.
• W2164910651 hasConcept C187345961 @default.
• W2164910651 hasConcept C190283241 @default.
• W2164910651 hasConcept C199835354 @default.
• W2164910651 hasConcept C27740335 @default.
• W2164910651 hasConcept C2778150266 @default.
• W2164910651 hasConcept C2778367456 @default.
• W2164910651 hasConcept C2778506107 @default.
• W2164910651 hasConcept C2780963305 @default.
• W2164910651 hasConcept C29537977 @default.
• W2164910651 hasConcept C502942594 @default.
• W2164910651 hasConcept C55493867 @default.
• W2164910651 hasConcept C86339819 @default.
• W2164910651 hasConcept C86803240 @default.
• W2164910651 hasConcept C9743823 @default.
• W2164910651 hasConceptScore W2164910651C104317684 @default.
• W2164910651 hasConceptScore W2164910651C120089663 @default.
• W2164910651 hasConceptScore W2164910651C1292079 @default.
• W2164910651 hasConceptScore W2164910651C153911025 @default.
• W2164910651 hasConceptScore W2164910651C170493617 @default.
• W2164910651 hasConceptScore W2164910651C185592680 @default.
• W2164910651 hasConceptScore W2164910651C187345961 @default.
• W2164910651 hasConceptScore W2164910651C190283241 @default.

• next